Form 4: Evolent Health Executive Daniel McCarthy Reports Stock Transactions

Daniel McCarthy, President of Evolent Health, reports acquisition and disposal of Class A Common Stock, including shares withheld for tax obligations and vesting of restricted stock units.

Summary

• Daniel McCarthy, President of Evolent Health, filed a Form 4 detailing changes in beneficial ownership of Evolent Health, Inc. [EVH] stock.
• On March 1, 2025, 15,143 shares of Class A Common Stock were disposed of at $8.99 to cover tax obligations related to vesting restricted stock units.
• On March 3, 2025, McCarthy acquired 156,683 shares of Class A Common Stock and 87,585 shares of Class A Common Stock at $0.
• Also on March 3, 2025, 39,501 shares of Class A Common Stock were disposed of at $8.77 to cover tax obligations related to the settlement of performance-based share units.
• Following these transactions, McCarthy beneficially owns 377,964 shares of Class A Common Stock.
• The transactions include the vesting of restricted stock units and the settlement of performance-based share units (PSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects standard executive compensation practices. The vesting of shares suggests performance targets were met, which is mildly positive, but the subsequent sale for tax obligations is a neutral event.

Positives

• The vesting of restricted stock units and settlement of performance-based share units indicate that performance metrics were met, which is a positive signal.
• McCarthy's increased holdings of Evolent Health stock could be interpreted as a sign of confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while standard, reduces McCarthy's overall holdings.

Risks

• Tax obligations arising from vesting equity can lead to dilution if shares are sold to cover these obligations.
• Future performance metrics may not be met, impacting the value of performance-based share units.

Future Outlook

The document indicates future vesting dates for restricted stock units on March 3, 2026, March 3, 2027, and March 3, 2028.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices involving stock options and restricted stock units.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the healthcare technology industry, used to align management's interests with those of shareholders.
• Companies like Cerner (now Oracle Health) and UnitedHealth Group also utilize stock options and restricted stock units as part of their compensation packages.
• The vesting schedules and performance metrics associated with these awards are typically designed to incentivize long-term growth and profitability, similar to industry peers.

Stakeholder Impact

• Shareholders may view the vesting of performance-based share units positively, as it indicates the achievement of performance goals.
• Employees may be motivated by the potential for similar equity-based compensation.

Next Steps

• Continued monitoring of insider transactions to assess management's sentiment and alignment with shareholder interests.
• Tracking the vesting of future restricted stock units on March 3, 2026, March 3, 2027, and March 3, 2028.

Key Dates